Skip to main content

Anti-Rheumatic Rx

Thromboembolic Risk with Tofacitinib in RA, PsA and UC

Aug 06, 2020

An analysis of the tofacitinib (Xeljanz) drug development program in patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA) and ulcerative colitis suggests a low level risk for venous (VTE) and arterial thromboembolism (ATE).  



In the last 2 years, observational data has

Read Article

Long-Term Rituximab in ANCA-Associated Vasculitis

Aug 06, 2020

The Annals of Internal Medicine reports that biannual rituximab infusions over 18 months was effective at maintaining remission in patients with antineutrophil cytoplasmic antibody–associated vasculitis (AAV).

Read Article

Methotrexate Not Associated with Interstitial Lung Disease

Aug 05, 2020

A case-controlled study shows that methotrexate (MTX) use in rheumatoid arthritis (RA) is not associated with interstitial lung disease (ILD) according to a report in the European Respiratory Journal.



Researchers examined the associatioin by comparing 410 RA patients with

Read Article

IL-1 Blockade: A Treatment at Last for Osteoarthritis?

Aug 05, 2020

The interleukin (IL)-1β inhibitor canakinumab (Ilaris) showed promise for preventing the need for hip or knee replacement among patients with osteoarthritis in an exploratory analysis of data from a randomized clinical trial, investigators reported.

Among patients enrolled in CANTOS, the pooled

Read Article

Wearable Technology to Measure Arthritis Outcomes

Aug 04, 2020

In this lockdown, virtual medicine, post-COVID world, wouldn't it be ideal to have an reliable digital readout on patient activity as a measure of health? A multicenter study from the University of Nebraska Medical Center and the University of Alabama at Birminghams have completed a novel

Read Article

Lovastatin Fails to Lower CRP and Activity in RA

Aug 04, 2020

Ridker and colleagues have shown that statins (3-hydroxy-3-methylglutaryl coenzyme-A (HMG Co-A) reductase inhibitors) are effective at treating hyperlipidaemia and lowering C-reactive protein levels; Aranaow and colleagues have shown that lovastatin, when given to rheumatoid arthritis (RA)

Read Article

Fighting Hydroxychloroquine Misinformation

Aug 03, 2020

JAMA Internal Medicine has posted an Editor's note on the use of hydroxychloroquine for COVID-19; noting the sequence of dysfunction since the president promoted its use on March 21, 2020, when he said “What do you have to lose? I’ll say it again: What do you have to lose? Take it

Read Article

More Rheumatology Fellow Advice from the Mentors

Aug 03, 2020

If you’re looking for some great advice to consider or rebuke, here is the generous guidance of nearly two dozen leaders in rheumatology who sincerely offer you their wisdom and best wishes.

Read Article

Uric Acid Targeting in Gout Management

Jul 31, 2020

A study from 2 gout clinics implementing different treatment strategies has shown that a treatment strategy that aims to strictly achieve low uric acid (UA) results in a higher a rate of targetd serum UA lowering and less gout flares.



Two gout clinics with 212 newly diagnosed gout

Read Article

RheumNow Podcast - Top 13 Rheumatology Centers (7-31-20)

Jul 31, 2020

Dr. Jack Cush reviews the news and TOP 13 list of Best Rheumatology Hospitals.

Read Article

Colchicine Benefits COVID-19 Patients

Jul 30, 2020

A proof-of-concept study published in Annals of Rheumatic Disease suggests that colchicine significantly improves COVID-19 outcomes.

Efficacy and safety must be determined in controlled clinical trials.he outbreak of COVID-19 posed the issue of urgently identifying treatment strategies.

Read Article

Methotrexate Improves Pegloticase Efficacy and Tolerability

Jul 29, 2020

The efficacy of intravenous pegloticase (PEG) therapy in gout can be limited by its toxicity, but when coadministered with weekly methotrexate, higher response rates and less toxicity was observed.



In published gout clinical trials, the PEG responder rate was 42%. Strategies to limit 

Read Article

The Burden of Gout

Jul 28, 2020

Danve and Neogi have an editorial in the current Arthritis & Rheumatology about the burden of gout that affects 41 million adults worldwide, according to the Global Burden of Disease Study 2017 (GBD 2017) also published in the same issue.

This makes gout twice as prevalent as rheumatoid

Read Article

SEMIRA Study: Best to Continue Low Dose Steroids in RA

Jul 28, 2020

The SEMIRA trial studied the  tapering vs continuing oral glucocorticoids in rheumatoid arthritis (RA) patients who achieved a low disease activity state (with tocilizumab) were more likely to show safety and better disease control with continuing steroids - even though two-thirds of patients

Read Article

RheumNow Podcast – COVID-19 Responds to Steroids (7.24.20)

Jul 24, 2020

Dr. Jack Cush reviews the News and Journal Reports from the past week on RheumNow.com.

Read Article

Low Risk of COVID in Biologic Treated Rheum Patients

Jul 23, 2020

In an Annals of Rheumatic Disease report, Italian investigators performed consecutive testing for SARS-CoV-2 (IgM and IgG) between 25 March to 25 May 2020 and compared test results between rheumatic disease (RMD) patients and the general population. 



Their study included 295

Read Article

For TNF Response in RA, Weight Matters

Jul 22, 2020

Patients with rheumatoid arthritis (RA) who were obese were significantly less likely to remain on treatment with tumor necrosis factor (TNF) inhibitors -- but so were those who were underweight, a large, long-term study determined.

Compared with patients with normal weight, patients in obesity

Read Article

Steroids and Tocilizumab in Cytokine Storm Syndrome

Jul 21, 2020

A recent study from the Netherlands has shown that patients with severe COVID-19-associated cytokine storm syndrome (CSS)  with high dose steroids and tocilizumab had a faster recovery, less need for invasive mechanical ventilation and fewer deaths when compared to CSS patients receiving

Read Article

Risankizumab Outduels Secukinumab in Psoriasis

Jul 20, 2020

The IMMerge trial has demonstrated the superiority of interleukin (IL)‐23 over IL-17A inhibition adults with plaque psoriasis.



This multicenter, phase 3, open‐label study enrolled 327 adult patients with chronic, moderate‐to‐severe plaque psoriasis who were randomised risankizumab (

Read Article

RECOVERY Trial: Dexamethasone in COVID-19

Jul 20, 2020

Inflammatory events following infection with SARS-CoV-2 can often worsen the morbid or mortal outcomes with COVID, yet it has been unclear if glucocorticoids may modulate inflammation-mediated damage and lung injury.  The RECOVERY trial reports that dexamethasone (DEX) use lowered 28-day

Read Article

Meloxicam Superior to Placebo and Cognitive Behavioral Therapy in Knee OA

Jul 20, 2020

Pain management in knee osteoarthritis (OA) is confounded by studies showing less is equal to usual standards of care. A recent trial showed that meloxicam was superior to placebo or cognitive behavioral therap (CBT); although the differences were small. 

Read Article
Bisphosphonate therapy may be protective against radiographic knee OA progression in early‐stage patients (KL grade < 2) (HR 0.53), especially non-obese. Study from 1977 women in the Osteoarthritis Initiative. https://t.co/tZhovfMWTh

Dr. John Cush RheumNow ( View Tweet)

Jul 20, 2020
A randomized controlled trial testing dexamethasone for Covid-19 (the RECOVERY trial) showed that, compared with usual care, this corticosteroid drug reduced 28-day mortality in hospitalized patients. #COVID19 #SARSCoV2

NEJM NEJM ( View Tweet)

Jul 19, 2020
RheumNow Podcast is Up! Listen to Fauci! Watch it here>> https://t.co/dHq3fP85Ip or Listen to the Podcast>> https://t.co/LdHO7fKUCp

Dr. John Cush RheumNow ( View Tweet)

Jul 17, 2020
Regeneron/Sanofi have reported their US phase 3 trial of Kevzara (sarilumab) 400 mg given to 194 critically ill COVID-19 patients, requiring mechanical ventilation, did not meet its primary and key secondary endpoints when added to supportive care.

Dr. John Cush RheumNow ( View Tweet)

Jul 17, 2020
×